| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events
|
Goswami, Sangeeta
|
|
|
40 |
3 |
p. 249-251
|
article
|
| 2 |
Dietary modulation of the gut microbiome as an immunoregulatory intervention
|
Matson, Vyara
|
|
|
40 |
3 |
p. 246-248
|
article
|
| 3 |
Expanding the immunotherapy roadmap for hepatocellular carcinoma
|
Baretti, Marina
|
|
|
40 |
3 |
p. 252-254
|
article
|
| 4 |
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions
|
van Tienderen, Gilles S.
|
|
|
40 |
3 |
p. 226-230
|
article
|
| 5 |
Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients
|
Sesques, Pierre
|
|
|
40 |
3 |
p. 236-237
|
article
|
| 6 |
Inspire, impact, improve
|
Mao, Steve
|
|
|
40 |
3 |
p. 219-220
|
article
|
| 7 |
Intratumoral plasma cells: More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?
|
Teillaud, Jean-Luc
|
|
|
40 |
3 |
p. 240-243
|
article
|
| 8 |
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
|
Patil, Namrata S.
|
|
|
40 |
3 |
p. 289-300.e4
|
article
|
| 9 |
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma
|
Yamamoto, Shun
|
|
|
40 |
3 |
p. 238-240
|
article
|
| 10 |
Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy
|
Vincent, Michael P.
|
|
|
40 |
3 |
p. 255-276
|
article
|
| 11 |
Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies
|
Day, Chi-Ping
|
|
|
40 |
3 |
p. 231-232
|
article
|
| 12 |
Stem-cell-like T cells have a specific entry gate to the tumor
|
Held, Werner
|
|
|
40 |
3 |
p. 243-245
|
article
|
| 13 |
The proteogenomic subtypes of acute myeloid leukemia
|
Jayavelu, Ashok Kumar
|
|
|
40 |
3 |
p. 301-317.e12
|
article
|
| 14 |
Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs
|
Zhao, Shen
|
|
|
40 |
3 |
p. 233-235
|
article
|
| 15 |
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
|
Wang, Zi-Xian
|
|
|
40 |
3 |
p. 277-288.e3
|
article
|
| 16 |
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy
|
Asrir, Assia
|
|
|
40 |
3 |
p. 318-334.e9
|
article
|
| 17 |
With one eye on the future
|
Caldas, Carlos
|
|
|
40 |
3 |
p. 221-225
|
article
|
Journal description